# Argenx Q3 2026 Earnings: 3 Key Takeaways

> Argenx reports $1.7B quarterly sales and expansion plans for long-term investors.
- Title: Argenx Q3 2026 Earnings: 3 Key Takeaways · The Motley Fool
- Summary: Argenx reports $1.7B quarterly sales and expansion plans for long-term investors. Argenx achieved $1.7 billion in Q3 2026 product sales with 54%…
- Keywords: argenx, vyvgart, q3 2026, pipeline expansion, operating profit, vision 2030, finance, money, 2026, Earnings, Key, Takeaways
- Source: The Motley Fool — https://fool.com/earnings/takeaways/2026/10/23/argenx-3-key-takeaways-for-long-term-investors
- Author: The Motley Fool Team
- Published: 2026-10-23T11:05:02+00:00
- Read time: 1 min
- Topics: argenx, vyvgart, q3 2026, pipeline expansion, operating profit, vision 2030, finance, money
## VYVGART Sales Growth
Product revenue rose 54% year-over-year due to increased patient adoption for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.

> Product net sales were $1.7 billion, representing growth of 54% year-over-year and 13% quarter-over-quarter.
## Pipeline Expansion
Argenx is advancing empasiprubart for multifocal motor neuropathy and FB102 for celiac disease to reduce dependency on a single drug.

> We're advancing empasiprubart toward its first phase 3 readout in MMN. And we had positive phase 2 results for FB102 in celiac disease, just months after the Forte acquisition.
## Operating Profit
Operating profit reached $486 million as top-line gains covered higher research and development expenses.

> Operating profit reached $486 million as top-line gains covered higher research and development expenses, allowing management to fund 10 clinical-stage molecules without eroding profitability.
## 2027 Product Launches
Argenx plans up to five potential product launches in 2027 to mark significant progress toward Vision 2030.

> 2027 will be an important year in the evolution of argenx with 5 potential launches across our portfolio.
## Key takeaway

Argenx achieved $1.7 billion in Q3 2026 product sales with 54% year-over-year growth in VYVGART and plans for five 2027 product launches.